Abstract: The present invention provides an isolated nucleic acid sequence encoding saitohin (STH), an isolated nucleic acid sequence that hybridizes to said sequence, and a purified protein encoded by said nucleic acid sequences. The present invention also provides a purified STH protein, and a method of making STH protein. The present invention is further directed to an antibody specific for STH, and a method for producing said antibody. Additionally, the present invention discloses a vector comprising a nucleic acid sequence encoding STH, a host cell transformed with said vector, and transgenic nonhuman animals. The present invention further provides methods for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease, and for assessing said subject's prognosis. Finally, the present invention discloses kits for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease.

Abstract: Differentially expressed genes and profiles of differentially expressed genes associated with hemodynamic shear stress in vivo in mammalian vasculature are provided. Methods for identifying such profiles and using these profiles to identify and target regions of the vasculature with anti-atherogenic therapies are provided. Also provided are methods of identifying agents which modulate a gene of the profile for use in preventing atherogenesis and treating atherosclerosis.

Abstract: Methods of diagnosing a tauopathy and predicting whether a subject will develop a tauopathy are provided. Also provided are antibody preparations that specifically bind to tau phosphorylated at tyr394 and/or tyr310. Methods of inhibiting tau phosphorylation in a cell and methods of treating a subject having a tauopathy are additionally provided. Methods of treating a subject at risk for a tauopathy are also provided. Additionally, non-human mammals comprising a transgene encoding an abl tyrosine kinase are provided. Also provided are methods of evaluating whether a compound inhibits development of a tauopathy.

Abstract: The invention provides transgenic mice comprising tau transgenes, and methods of preparing and using the transgenic mice. For example, the invention provides a transgenic mouse, the genome of the cells of which stably comprise a DNA molecule which comprises a human genomic DNA sequence comprising a human tau promoter and which DNA sequence encodes human tau.

Abstract: The instantaneous value of an intermediate waveform I is the instantaneous value of a unipolar waveform U multiplied through amplification by an upscaling factor UF of 1.5. A plateau value P is subtracted from the intermediate value I, and the result of this subtraction is multiplied by a multiplication factor MF of 0.6. The result of the multiplication is added to the plateau value P, which sum becomes an auxiliary waveform A. During the fall-below periods F, the value of a combined waveform C is arranged to follow whichever is the highest of the auxiliary value A and the plateau value P. Outside the fall-below periods, the value of the combined waveform C follows whichever is the highest of the unipolar value U and the plateau value P. This combined waveform C has, for a given plateau level P, a narrower fall-below window. Phase-chopping thus has an effect on the power of the output signal over a greater range of the cycle than can be provided by the corresponding prior art arrangement.

Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound and a bone enhancing agent, such as vitamin D.

Abstract: The invention provides transgenic mice comprising tau transgenes, and methods of preparing and using the transgenic mice. For example, the invention provides a transgenic mouse, the genome of the cells of which stably comprise a DNA molecule which comprises a human genomic DNA sequence comprising a human tau promoter and which DNA sequence encodes human tau.

Abstract: An electronic document management system. The system includes a document entry module; a document management module; and a real time digital certificate generator for effecting electronic signatures. In the preferred embodiment, the system further includes a document repository module for storing documents and for accessing documents.

Abstract: Stabilized lanthanum carbonate compositions containing a monosaccharide or disaccharide stabilizing agent are disclosed. Subjects having hyperphosphatemia can be treated by administering a pharmaceutical composition containing a therapeutically effective amount of the stabilized lanthanum carbonate formulation.

Abstract: A novel class of thermal hysteresis (antifreeze) proteins (THP) that have up to 100 times the specific activity of fish antifreeze proteins has been isolated and purified from the mealworm beetle, Tenebrio molitor. Internal sequencing of the proteins, leading to cDNA cloning and production of the protein in bacteria has confirmed the identity and activity of the 8.4 to 10.7 kDa THP. They are novel Thr- and Cys-rich proteins composed largely of 12-amino-acid repeats of cys-thr-xaa-ser-xaa-xaa-cys-xaa-xaa-ala-xaa-thr. At a concentration of 55 ?g/mL, the THP depressed the freezing point 1.6° C. below the melting point, and at a concentration of ˜1 mg/mL the THP or its variants can account for the 5.5° C. of thermal hysteresis found in Tenebrio larvae. The THP function by an adsorption-inhibition mechanism and produce oval-shaped ice crystals with curved prism faces.

Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detectiing human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

Abstract: A method for identifying a desired binding agent that interferes with the interaction between a protein, protein fragment, polypeptide or a peptide and a binding surrogate. The method comprises combining the protein, protein fragment, polypeptide or peptide, the binding surrogate and a binding agent. Detecting a decrease in the interaction between the protein, protein fragment, polypeptide or peptide from the binding surrogate indicates that the binding agent interferes with the interaction. Proteins useful in the method include the tau protein phosphorylated at threonine (231), the Amyloid Precursor Protein (APP) phosphorylated at threonine (668 and cdc25 phosphorylated at threonine (48). Compounds identified by the method are useful in the treatment of Alzheimers' disease and cancer.

Abstract: The present invention provides an isolated nucleic acid sequence encoding saitohin (STH), an isolated nucleic acid sequence that hybridizes to said sequence, and a purified protein encoded by said nucleic acid sequences. The present invention also provides a purified STH protein, and a method of making STH protein. The present invention is further directed to an antibody specific for STH, and a method for producing said antibody. Additionally, the present invention discloses a vector comprising a nucleic acid sequence encoding STH, a host cell transformed with said vector, and transgenic nonhuman animals. The present invention further provides methods for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease, and for assessing said subject's prognosis. Finally, the present invention discloses kits for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease.

Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

Abstract: A method of gutting a cephalopod, such as squid, the cephalopod having an outer mantle containing internal organs, and the method comprising retaining the outer mantle at a fixed distance from a central axis while rotating the mantle about the said axis whereby the internal organs are subjected to a centrifugal force sufficient to eject the organs outwardly through an open end of the mantle.

Abstract: A method of gutting a cephalopod, such as squid, the cephalopod having an outer mantle containing internal organs, and the method comprising retaining the outer mantle at a fixed distance from a central axis while rotating the mantle about the said axis whereby the internal organs are subjected to a centrifugal force sufficient to eject the organs outwardly through an open end of the mantle.

Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detectiing human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

Abstract: A storage case for small format memory cards is taught which utilizes those sections of known and existing computer furniture specifically designed to receive compact disc jewel cases to thereby allow for more reliable storage of small format memory cards. The storage case includes a compact disc jewel case without a disc retaining mechanism therein. A foam insert resides within the compact disc jewel case and has at least one precut cut-out section therein which is removable to provide at least one space in the foam insert to receive a small format memory card. The jewel case is preferably formed from a clear plastic material and there is preferably an insert sheet adapted to be retained proximate to a front wall of the jewel case.

Abstract: The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

Abstract: The use of a calcium intracellular store inactivator for inhibiting cell growth is disclosed; for example, thapsigargin or a derivative may be used to inhibit intraocular lens cell growth. Formulations include an emulsion of the compound for coating an IOL, either ex vivo or in vivo.